Moderna Slumps as FDA OKs Pfizer Booster for Those Aged 12+
Investing.com
Published Jan 04, 2022 04:02
By Dhirendra Tripathi
Investing.com – Moderna stock (NASDAQ:MRNA) plunged 8% Monday as the Food and Drug Administration expanded the use of the Covid-19 shots made by rivals Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) while saying it continues to review data concerning all available vaccines.
The drug regulator today said a single booster dose of the Pfizer-BioNTech Covid-19 vaccine outweighs the potential risks in children 12 years and older and is thus allowed to be administered.
The body also authorized a third dose for immunocompromised children 5 years and older. It also shortened the time between the completion of primary vaccination of the Pfizer-BioNTech Covid-19 vaccine and a booster dose to at least five months for all eligible individuals older than 12 years, leaving unchanged the six-month gap for those vaccinated by Moderna’s shot, reports said.
The FDA decision comes as the Omicron variant rages through the U.S. and many other countries. Daily infections in U.S. along have crossed 700,000, a pandemic record while the world is averaging 1.5 million new cases every day.
The FDA said it reviewed real-world data from Israel, including safety data from more than 6,300 individuals 12 through 15 years of age who received a booster dose of the vaccine at least five months following completion of the primary two-dose vaccination series.
Get The App
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.